Several preclinical studies have revealed that HDAC inhibitors act as potent radiosensitizers in various cancers, including GBM [52–55], breast cancer [56], colorectal cancer [57], head and neck cancer [58], non-small-cell lung cancer [59], melanoma [60], and prostate cancer [53]. Here, HDAC9 is linked to cancer.